Literature DB >> 25658027

Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness.

Dorota Fiszer1, Marie-Anne Shaw, Nickla A Fisher, Ian M Carr, Pawan K Gupta, Elizabeth J Watkins, Daniel Roiz de Sa, Jerry H Kim, Philip M Hopkins.   

Abstract

BACKGROUND: Variants in RYR1 are associated with the majority of cases of malignant hyperthermia (MH), a form of heat illness pharmacogenetically triggered by general anesthetics, and they have also been associated with exertional heat illness (EHI). CACNA1S has also been implicated in MH. The authors applied a targeted next-generation sequencing approach to identify variants in RYR1 and CACNA1S in a cohort of unrelated patients diagnosed with MH susceptibility. They also provide the first comprehensive report of sequencing of these two genes in a cohort of survivors of EHI.
METHODS: DNA extracted from blood was genotyped using a "long" polymerase chain reaction technique, with sequencing on the Illumina GAII or MiSeq platforms (Illumina Inc., USA). Variants were assessed for pathogenicity using bioinformatic approaches. For further follow-up, DNA from additional family members and up to 211 MH normal and 556 MH-susceptible unrelated individuals was tested.
RESULTS: In 29 MH patients, the authors identified three pathogenic and four novel RYR1 variants, with a further five RYR1 variants previously reported in association with MH. Three novel RYR1 variants were found in the EHI cohort (n = 28) along with two more previously reported in association with MH. Two other variants were reported previously associated with centronuclear myopathy. The authors found one and three rare variants of unknown significance in CACNA1S in the MH and EHI cohorts, respectively.
CONCLUSIONS: Targeted next-generation sequencing proved efficient at identifying diagnostically useful and potentially implicated variants in RYR1 and CACNA1S in MH and EHI.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25658027      PMCID: PMC4472733          DOI: 10.1097/ALN.0000000000000610

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  47 in total

1.  Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia.

Authors:  S L Stewart; K Hogan; H Rosenberg; J E Fletcher
Journal:  Clin Genet       Date:  2001-03       Impact factor: 4.438

2.  Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.

Authors:  Jose Miguel Eltit; Roger A Bannister; Ong Moua; Francisco Altamirano; Philip M Hopkins; Isaac N Pessah; Tadeusz F Molinski; Jose R López; Kurt G Beam; Paul D Allen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

Review 3.  Mutations in RYR1 in malignant hyperthermia and central core disease.

Authors:  Rachel Robinson; Danielle Carpenter; Marie-Anne Shaw; Jane Halsall; Philip Hopkins
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

4.  Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia.

Authors:  Lucia Galli; Alfredo Orrico; Stefania Lorenzini; Stefano Censini; Michela Falciani; Antonello Covacci; Vincenzo Tegazzin; Vincenzo Sorrentino
Journal:  Hum Mutat       Date:  2006-08       Impact factor: 4.878

5.  Evolution and functional impact of rare coding variation from deep sequencing of human exomes.

Authors:  Jacob A Tennessen; Abigail W Bigham; Timothy D O'Connor; Wenqing Fu; Eimear E Kenny; Simon Gravel; Sean McGee; Ron Do; Xiaoming Liu; Goo Jun; Hyun Min Kang; Daniel Jordan; Suzanne M Leal; Stacey Gabriel; Mark J Rieder; Goncalo Abecasis; David Altshuler; Deborah A Nickerson; Eric Boerwinkle; Shamil Sunyaev; Carlos D Bustamante; Michael J Bamshad; Joshua M Akey
Journal:  Science       Date:  2012-05-17       Impact factor: 47.728

6.  Evidence for related myopathies in exertional heat stroke and malignant hyperthermia.

Authors:  P M Hopkins; F R Ellis; P J Halsall
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

7.  Genetic diagnosis of familial breast cancer using clonal sequencing.

Authors:  Joanne E Morgan; Ian M Carr; Eamonn Sheridan; Carol E Chu; Bruce Hayward; Nick Camm; Helen A Lindsay; Chris J Mattocks; Alexander F Markham; David T Bonthron; Graham R Taylor
Journal:  Hum Mutat       Date:  2010-04       Impact factor: 4.878

8.  Multiple regions of RyR1 mediate functional and structural interactions with alpha(1S)-dihydropyridine receptors in skeletal muscle.

Authors:  Feliciano Protasi; Cecilia Paolini; Junichi Nakai; Kurt G Beam; Clara Franzini-Armstrong; Paul D Allen
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

9.  The role of CACNA1S in predisposition to malignant hyperthermia.

Authors:  Danielle Carpenter; Christopher Ringrose; Vincenzo Leo; Andrew Morris; Rachel L Robinson; P Jane Halsall; Philip M Hopkins; Marie-Anne Shaw
Journal:  BMC Med Genet       Date:  2009-10-13       Impact factor: 2.103

10.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  23 in total

Review 1.  A comprehensive review of malignant hyperthermia: Preventing further fatalities in orthopedic surgery.

Authors:  Jennifer L Smith; Meaghan A Tranovich; Nabil A Ebraheim
Journal:  J Orthop       Date:  2018-05-07

2.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

3.  Is Heat Intolerance State or Trait?

Authors:  Yuri Hosokawa; Rebecca L Stearns; Douglas J Casa
Journal:  Sports Med       Date:  2019-03       Impact factor: 11.136

4.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

5.  Genetic epidemiology of malignant hyperthermia in the UK.

Authors:  D M Miller; C Daly; E M Aboelsaod; L Gardner; S J Hobson; K Riasat; S Shepherd; R L Robinson; J G Bilmen; P K Gupta; M-A Shaw; P M Hopkins
Journal:  Br J Anaesth       Date:  2018-08-17       Impact factor: 9.166

6.  In Reply.

Authors:  Philip M Hopkins; Dorota Fiszer; Marie-Anne Shaw; Daniel Roiz de Sa
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

7.  Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings.

Authors:  Yuri Hosokawa; Douglas J Casa; Henry Rosenberg; John F Capacchione; Emmanuel Sagui; Sheila Riazi; Luke N Belval; Patricia A Deuster; John F Jardine; Stavros A Kavouras; Elaine C Lee; Kevin C Miller; Sheila M Muldoon; Francis G O'Connor; Scott R Sailor; Nyamkhishig Sambuughin; Rebecca L Stearns; William M Adams; Robert A Huggins; Lesley W Vandermark
Journal:  J Athl Train       Date:  2017-03-07       Impact factor: 2.860

Review 8.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

9.  Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia.

Authors:  A H Schiemann; K M Stowell
Journal:  Br J Anaesth       Date:  2016-05-04       Impact factor: 9.166

10.  Assessing the pathogenicity of RYR1 variants in malignant hyperthermia.

Authors:  A Merritt; P Booms; M-A Shaw; D M Miller; C Daly; J G Bilmen; K M Stowell; P D Allen; D S Steele; P M Hopkins
Journal:  Br J Anaesth       Date:  2017-04-01       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.